Scientists describe in Nature Immunology an entirely new molecular process in mice that triggers T cell-driven inflammation and causes different auto-immune diseases. In a study published online Dec. 17, 2019, researchers at Cincinnati...
Autoimmune Disease
Category
AstraZeneca’s Anifrolumab Demonstrates Superiority Across Multiple Efficacy Endpoints in Patients with Systemic Lupus Erythematosus in Phase 3 TULIP 2 Trial
AstraZeneca presented data from TULIP 2, a phase 3 trial evaluating anifrolumab for the treatment of moderate to severe systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Annual Meeting 2019 in Atlanta. Anifrolumab demonstrated...
Amgen and Allergen Submit Biologic License Application to U.S. FDA for ABP 798, Biosimilar Candidate to Rituxan® (rituximab)
Amgen and Allergan announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan® (rituximab), which has been approved for hematologic and autoimmune indications. The...
Early-Stage UK Biotech Pathios Therapeutics Taps into Australian Gov-Connected Fund & Silicon Valley for $8.8m
Pathios Therapeutics, a UK biotech venture founded in 2017, builds strong relationships with Down Under for money and intellectual capital, recently securing $8.8m part of which comes from MRCF— Australia and New Zealand government fund—as well as an ongoing...
World’s first Drug to Inhibit ITK and BTK for GvHD & Autoimmune Disease
A Korean biotech claims its DWP213388 is the world’s first autoimmune disease treatment candidate and experimental drug to inhibit both interleukin-2-inducible T-cell kinase (ITK) and Bruton’s tyrosine kinase (BTK)—both targets for immune cell activation. The sponsor...
Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis
Equillium announced that the U.S. Food and Drug Administration has granted Fast Track designation for itolizumab for the treatment of lupus nephritis. The FDA’s Fast Track program is designed to facilitate the development of new treatments for serious or...
Cedars-Sinai Receives $20m Gift to Launch the Kao Autoimmunity Institute, Including Clinical Research
Cedars-Sinai today announced a $20 million gift from Dr. and Mrs. H. Kao and the Kao Family Foundation to create the Kao Autoimmunity Institute to advance research and the treatment of rheumatologic diseases. This gift helps establish the Scleroderma Program within...
Experimental Lupus Nephritis Drug Performs Well in Phase III Trials Sending Sponsor’s Stock Price Up
Fantastic clinical trials results for an investigational drug that treats kidney inflammation caused by lupus, an autoimmune disease. Aurinia Pharmaceuticals stock price has shot up 78.8% as a result. Lupus Nephritis can Kill Lupus nephritis, affecting about three (3)...
Upadacitinib Appears to Help Ankylosing Spondylitis Patients During Phase II Trial
AbbVie’s Executive Medical Director, Dr. Aileen Lorenzo Pangan, recently discussed the American-biopharma company’s commitment to advancing the standard of care for patients with rheumatic diseases such as ankylosing spondylitis (AS). With thirty-eight abstracts...
Phase III Trial Bodes Well for Investigational Treatment for Vasculitis Treatment Sending ChemoCentryx Shares up 250%
The ADVOCATE trial, sponsored by ChemoCentryx, assessed the safety of CCX168(avacopan) in inducing and sustaining remission in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). To everyone’s surprise a set of conclusive findings...
Clinical Trial Concerning Complexity of Cancer in Autoimmune Compromised Patients
At the American College of Rheumatology 2019 Annual Meeting last week, it was mentioned that earlier this year, the National Cancer Institute (NCI) launched a phase 1 clinical trial to evaluate how effective nivolumab is...
Prader-Willi syndrome Investigational Drug into FDA Fast Track Mode while Phase III Study Continues
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Levo Therapeutics’ LV-101 (intranasal carbetocin) for the treatment of Prader-Willi syndrome (PWS). Presently the biotech venture is sponsoring a Phase III clinical study of intranasal...
Dr. Susan Manzi, MD,MPH with Allegheny Health Network a Globally Recognized Lupus Investigator
Dr. Susan Manzi, MD, MPH, with Allegheny Health Network, an internationally known lupus clinical researcher and investigator, was selected for the 2019 Distinguished Clinical Investigator Award by the American College of Rheumatology. Dr. Manzi is among an elite group...
Decade of Walter and Eliza Hall Institute Research Leads to Potential New Possible Way to Combat Lupus, HIV
An important study led by Australian researchers from the Walter and Eliza Hall Institute in Melbourne and colleagues discovered in laboratory models that strong inflammatory signals caused by malaria infection activate molecules that trigger the production of highly...
Mayo Clinic-led Study Finds Associations between Rheumatoid Arthritis & Other Diseases
A Mayo Clinic-led study centering on 3,276 patients discovered that people with inflammatory bowel disease, Type 1 diabetes or blood clots may face higher risks for developing rheumatoid arthritis and rheumatoid arthritis patients face risk of developing heart...
X4 Pharma Receives Breakthrough Therapy Designation from FDA for Mavorixa for the Treatment of WHIM Syndrome
X4 Pharmaceuticals announced the U.S. FDA has granted Breakthrough Therapy Designation for mavorixafor (X4P-001) for the treatment of adult patients with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome. A Breakthrough Therapy Designation...
Feinstein Institutes for Medical Research Investigator Pursues Lupus Treatment Advances
Dr. Richard Furie, with Northwell Health’s The Feinstein Institutes for Medical Research, will publish and present data describing the clinical benefit of anifrolumab for patients with lupus in Lancet Rheumatology and at the American College of Rheumatology’s Annual...
University of Pennsylvania Study Reveals FDA Recommended Dose for Pemphigus May Not be Ideal
Clinical investigators from University of Pennsylvania, Perelman School of Medicine, reveal that a lymphoma-dose regimen of rituximab, a medication regularly used to treat lymphoma and rheumatoid arthritis, is more likely to put patients with pemphigus into complete...
German SciRhom Ready to Pursue Development of Monoclonal Antibodies against IRhom2 to Treat Major Autoimmune Diseases
German SciRhom GmbH and New York’s Hospital for Special Surgery (HSS) have collaborated on proof-of-concept studies leading to the announcement of the first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways such...
A More Targeted CAR-T Cell-based Therapy for Myasthenia Gravis Moves into Clinical Trial with University of Florida
Emerging biopharmaceutical cell and gene therapy venture Cartesian Therapeutics announced that it has initiated a Phase I/2 clinical trial targeting its lead CAR-T candidate, Descartes-08, in patients with generalized myasthenia gravis (GMG). Generalized Myasthenia...